Burkholderia cepacia: Dangers of a phytopathogen organism for patients with cystic fibrosis;Burkholderia cepacia: Les dangers d'un micro-organisme phytopathogene pour les patients atteints de mucoviscidose

Annales de Biologie Clinique

Volumn 59, Issue 3, 2001, Pages 259-269

  Segonds, C ^a   Chabanon, G ^a  

^a CHU RANGUEIL   (France)

Author keywords

Burkholderia cepacia; Cystic fibrosis

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BURKHOLDERIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA GLADIOLI; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA STABILIS; BURKHOLDERIA VEITNAMIENSIS; CROSS INFECTION; CYSTIC FIBROSIS; DEATH; HOSPITAL INFECTION; HUMAN; OPPORTUNISTIC INFECTION; PREVALENCE; REVIEW;

BURKHOLDERIA CEPACIA; BURKHOLDERIA INFECTIONS; CROSS INFECTION; CYSTIC FIBROSIS; HUMANS; OPPORTUNISTIC INFECTIONS; PREVALENCE;

ANIMALIA; BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA GLADIOLI; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA STABILIS; BURKHOLDERIA VIETNAMIENSIS; NEGIBACTERIA;

EID: 0034966950     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp.nov
2. The epidemiology of nosocomial epidemic Pseudomonas cepacia infections
3. Burkholderia cepacia bacteremia: A retrospective analysis of 70 episodes
4. Pseudomonas cepacia infection in cystic fibrosis: An emerging problem
5. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis
6. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome
7. Pseudomonas cepacia: An emerging pathogen in chronic granulomatous disease
8. Infection with Pseudomonas cepacia in chronic granumomatous disease: Role of nonoxidative killing by neutrophils in host defence
9. Pseudomonas cepacia bacteremia in children with sickle cell hemoglobinopathies
10. Recovery of Pseudomonas gladioli from respiratory tract specimens of patients with cystic fibrosis
11. Lung infection with Burkholderia gladioli in a child with cystic fibrosis: Acute clinical and spirometric deterioration
12. Infections in patients with cystic fibrosis following lung transplantation
13. Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: Report of two successfully treated cases
14. Four additional cases of Burkholderia gladioli infection with microbiological correlates and review
15. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis
16. Empyema and bloodstream infection caused by Burkholderia gladioli in a patient with cystic fibrosis after lung transplantation
17. Production and utilization of pyochelin by clinical isolates of Pseudomonas cepacia
18. Cepabactin from Pseudomonas cepacia, a new type of siderophore
19. Isolation of a novel siderophore from Pseudomonas cepacia
20. Ornibactins-a new family of siderophores from Pseudomonas
21. Siderophore production by cystic fibrosis isolates of Barkholderia cepacia
22. Role of omibactin biosynthesis in the virulence of Burkholderia cepacia: Characterization of pvdA, the gene encoding L-ornithineN(5)-oxygenase
23. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide
24. Lipopolysaccharide (LPS) from Burkholderia cepacia is more active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in stimulating tumor necrosis factor alpha from human monocytes
25. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products
26. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia
27. Pulmonary function, serum markers of inflammation, and IgG antibodies to core lipopolysaccharide of Burkholderia cepacia in adults with cystic fibrosis, following colonization with Burkholderia cepacia
28. Structurally variant classes of pilus appendage fibers coexpressed from Burkholderia (Pseudomonas) cepacia
29. Identification of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis
30. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia
31. Invasion and intracellular survival of Burkholderia cepacia
32. Purification and characterization of an extracellular protease from Pseudomonas cepacia
33. Molecular analysis of hemolytic and phospholipase C activities of Pseudomonas cepacia
34. A nonhemolytic phospholipase C from Burkholderia cepacia
35. Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes
36. Influence of Pseudomonas aeruginosa exoproducts on virulence factor production in Burkholderia cepacia: Evidence of interspecies communication
37. Pseudomonas cepacia adherence to respiratory epithelial cells is enhanced by Pseudomonas aeruginosa
38. Burkholderia cepacia: Medical, taxonomic and ecological issues
39. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia isolates from a nosocomial outbreak
40. Typage moléculaire par électrophorèse en champ pulsé de souches de Pseadomonas (Burkholderia) cepacia isolées lors d'une infection nosocomiale
41. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the republic of Ireland
42. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers
43. Molecular epidemiology of Pseudomonas cepacia determined by polymerase chain reaction ribotyping
44. Comparison of different PCR approaches for characterisation of Burkholderia (Pseudomonas) cepacia isolates
45. Arbitrarily primed polymerase chain reaction as a rapid method to differentiate crossed from independant Pseudomonas cepacia infections in cystic fibrosis patients
46. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping
47. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: Analysis by randomly amplified polymorphic DNA fingerprinting
48. Genotypic analysis of Burkholderia cepacia isolates from 13 cystic fibrosis centers
49. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates
50. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia
51. Infections and pseudoinfections due to povidone-iodine solution contaminated with Pseudomonas cepacia
52. Analysis of strains of Burkholderia (Pseudomonas) cepacia isolated in a nosocomial outbreak by biochemical and genomic typing
53. Clinical features of Pseudomonas cepacia pneumonia in an epidemic among immunocompromised patients
54. Ventilator temperature sensors: An unusual source of Pseudomonas cepacia in nosocomial infection
55. Molecular epidemiological investigation using a randomly amplified polymorphic DNA assay of Burkholderia cepacia isolates from nosocomial outbreaks
56. An outbreak of Burkholderia (formely Pseudomonas) cepacia respiratory tract colonization and infection associated with nebulized albuterol therapy
57. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis
58. Epidemiology of Pseudomonas cepacia colonization among patients with cystic fibrosis
59. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis
60. Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis
61. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?
62. Burkholderia cepacia and cystic fibrosis: Do natural environments present a potential hazard?
63. Genotypic and phenotypic relationships in Burkholderia cepacia isolated from cystic fibrosis patients and the environment
64. Agricultural use of Burkholderia (Pseudomonas) cepacia: A threat to human health?
65. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain
66. Distribution of genes encoding putative transmissibility factors among epidemic and non epidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom
67. Identification of IS1356, a new insertion sequence, and its association with IS402 in epidemic strains of Burkholderia cepacia infecting cystic fibrosis patients
68. Proposal of Burkholderia gen.nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb.nov
69. Sour skin, a bacterial rot of onion bulbs
70. Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex
71. Identification and population structure of Burkholderia stabilis sp.nov. (formerly Burkholderia cepacia genomovar IV)
72. Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp.nov. for N2-fixing isolates from rice in Vietnam
73. Multiple replicons constituting the genome of Pseudomonas cepacia 17616
74. A physical genome map of the Burkholderia cepacia type strain
75. Genomic complexity and plasticity of Burkholderia cepacia
76. Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis
77. Comparison of two selective media developed to isolate Pseudomonas cepacia from patients with cystic fibrosis
78. Comparative evaluation of selective media for isolation of Pseudomonas cepacia from cystic fibrosis patients and environmental sources
79. Impact of microbiology pratice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis
80. Recommandation pour l'analyse bactériologique des prélèvements d'expectoration chez les patients atteints de mucoviscidose
81. Use of bronchoalveolar lavage semiquantitative cultures in cystic fibrosis
82. Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis
83. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium
84. Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis
85. Isolation of Burkholderia cepacia by enrichment
86. Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis
87. PCR-RFLP analysis of the flagellin sequences for identification of Burkholderia pseudomallei and Burkholderia cepacia from clinical isolates
88. DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III
89. Resistance mechanisms in Pseadomonas aeruginosa and other nonfermentative Gram-negative bacteria
90. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis
91. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia
92. Ceftazidime alone an in combination in patients with cystic fibrosis: Lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia